

# CURRICULUM VITAE

**Pablo Francisco Belaunzarán Zamudio**

---

## PERSONAL INFORMATION

---

**Address:** Av. Vasco de Quiroga 15, Col. Sección XVI  
Del. Tlalpan, México, D.F. C.P. 14080

**Phone (office):** 5487-0900, ext. 5502 & 5508

**Date of birth:** August 15, 1974

**Medical License (Mexico):** 3324426

**Member of the Mexican National Research System (SNI):** Level II (III levels)

## EDUCATION

---

- 2008-** **Johns Hopkins Bloomberg School of Public Health (JHSPH)**  
PhD candidate, International Health  
(Global Disease Epidemiology & Control)
- 2007-2008** **University of Oxford**  
M.Sc. in Global Health Sciences
- 2004-2006** **Universidad Nacional Autónoma de México (UNAM) / Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán” (INCMNSZ)**  
Infectious Diseases Specialist
- 2003** **London School of Hygiene and Tropical Medicine**  
Diploma in Tropical Medicine & Hygiene
- 2000-2004** **INCMNSZ**  
Internal Medicine Specialists
- 1994-1999** **UNAM**  
Physician Surgeon

## OTHER

---

- 2007** **University of Washington, Center for AIDS Research**  
Short Training in Epidemiology & Biostatistics

## **TEACHING EXPERIENCE**

---

- 2015-** **Universidad Nacional Autónoma de México**  
Associate Professor of Infectious Diseases for Medical Students, UNAM
- 2015-** **Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán**  
Course Professor for Internal Medicine Residents  
Course Professor for Infectious Diseases Fellows  
Course Professor for Pain Management Fellows (2016- )  
Course Professor for Geriatrics Fellows (2019- )
- 2007** **Department of International Health, JHSPH**  
Teaching Assistant, Introduction to International Health  
Teaching Assistant, Vaccine Development and Application
- 2005-2006** **Universidad Panamericana**  
Clinical Instructor, Infectious Diseases for Medical Students

## **LABORAL EXPERIENCE**

---

- 2014-** **Department of Infectious Diseases, INCMNSZ**  
Researcher in Medical Sciences "C"  
Head of HIV/AIDS Clinic
- 2015-2018** **School of Medicine, Universidad Nacional Autónoma de México**  
Técnico Académico "A" (Assistant Professor)
- 2014-2015** **Mexico City HIV/AIDS Program**  
Research Coordinator
- 2007** **Case Western Reserve University, Center for AIDS Research**  
Research Assistant
- 2006** **HIV/AIDS Clinic, INCMNSZ**  
Research Assistant

## ORIGINAL ARTICLES

---

- 35 Perez-Patrigeon S, Camiro-Zúñiga A, Jaramillo-Jante MR, **Belaunzarán-Zamudio PF**, *et al.* Immediate treatment of acute HIV in a tertiary healthcare center: bridging gaps in communication using smartphones. *HIV Med.* 2019 Mar 29.
- 34 Lopez Luis BA, Valdivia-Cayoja AR, **Belaunzarán-Zamudio PF**, Soto-Ramírez LE. An immunocompromised patient & multiorgan cystic echinococcosis. *QJM.* 2019 Mar 1;112(3):215-217.
- 33 Sierra-Madero JG, **Belaunzarán-Zamudio PF**, Crabtree-Ramírez B, Magis-Rodriguez C. Mexico's fragmented health system as a barrier to HIV care. *Lancet HIV.* 2019 Feb;6(2): e74-e75. doi: 10.1016/S2352-3018(18)30356-4.
- 32 Cano-Torres JO, Olmedo-Reneaum A, Esquivel-Sánchez JM, Camiro-Zuñiga A, Pérez-Carrisoza A, Madrigal-Iberri C, Flores-Miranda R, Ramírez-González LE, **Belaunzarán-Zamudio PF**. Progressive disseminated histoplasmosis in Latin America and the Caribbean in people receiving highly active antiretroviral therapy for HIV infection: A systematic review. *Med Mycol.* 2019 Jan 18. doi: 10.1093/mmy/myy143
- 31 Marfil-Garza BA, **Belaunzarán-Zamudio PF**, Gullias-Herrero A, *et al.* Risk factors associated with prolonged hospital length-of-stay: 18-year retrospective study of hospitalizations in a tertiary healthcare center in Mexico. *PLoS One.* 2018 Nov 8;13(11): e0207203.
- 30 Cano-Torres JO, Caro-Vega YN, Crabtree-Ramírez B, Sierra-Madero JG, **Belaunzarán-Zamudio PF**. Incidence and prevalence of Diabetes mellitus type 2 in people receiving care for HIV in a third level health care center in Mexico City. *Revista Médica MD.* 2018 October 18; 9(4):305-310
- 29 Caro-Vega Y, **Belaunzarán-Zamudio PF**, Crabtree-Ramírez B, Shepherd BE, Mejia F, Giganti MJ, Patterson P, Grinsztejn B, Wolff M, Pape JW, Padgett D, Castilho JL, McGowan C, Sierra-Madero JG. Trends in proportion of older HIV-infected people in care in Latin America and the Caribbean: a growing challenge. *Epidemiol Infect.* 2018 Jul;146(10):1308-1311.
- 28 Avila-Funes JA, Zamudio-Rodríguez A, Muñoz-Nevárez LA, **Belaunzarán-Zamudio PF**, *et al.* Correlates of depressive symptoms among older adults living with HIV. *Int J Geriatr Psychiatry.* 2018 Jun;33(9):1260-1264.
- 27 Zamudio-Rodríguez A, **Belaunzarán-Zamudio PF**, Sierra-Madero J, *et al.* Association between Frailty and HIV-Associated Neurodegenerative Disorders among Older Adults Living with HIV. *AIDS Res Hum Retroviruses.* 2018 May;34(5):449-455.
- 26 Caro-Vega Y, **Belaunzarán-Zamudio PF**, Crabtree-Ramírez BE, *et al.* Durability of Efavirenz Compared With Boosted Protease Inhibitor-Based Regimens in Antiretroviral-Naïve Patients in the Caribbean and Central and South America. *Open Forum Infect Dis.* 2018 Mar 2;5(3): ofy004.
- 25 De Boni RB, Peratikos MB, Shepherd BE, Grinsztejn B, Cortés C, Padgett D, Gotuzzo E, **Belaunzarán-Zamudio PF**, *et al.* Is substance use associated with HIV cascade outcomes in Latin America? *PLoS ONE* 2018 Mar 15;13(3): e0194228.
- 24 Wolff MJ, Cortes CP, Mejia FA, Padgett D, **Belaunzarán-Zamudio P**, *et al.* Evaluating the care cascade after antiretroviral therapy initiation in Latin America. *Int J STD AIDS.* 2018 Jan;29(1):4-12.

- 23 Valdés-Ferrer SI, Crispín JC, **Belaunzarán-Zamudio PF**, *et al.* Add-on Pyridostigmine Enhances CD4<sup>+</sup> T-Cell Recovery in HIV-1-Infected Immunological Non-Responders: A Proof-of-Concept Study. *Front Immunol.* 2017 Oct 18;8: 1301.
- 22 AIDS-defining Cancer Project Working Group for leDEA and COHERE in EuroCoord. Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. *Clin Infect Dis.* 2017 Oct 15;65(8):1316-1326.
- 21 **Belaunzarán-Zamudio PF**, Mosqueda-Gomez JL, Macias-Hernandez A, *et al.* Risk factors for prevalent hepatitis C virus-infection among inmates in a state prison system in Mexico. *PLoS One.* 2017 Jun 27;12(6): e0179931.
- 20 **Belaunzarán-Zamudio PF**, Mosqueda-Gomez JL, Macias-Hernandez A, *et al.* Burden of HIV, Syphilis, and Hepatitis B and C Among Inmates in a Prison State System in Mexico. *AIDS Res Hum Retroviruses.* 2017 Jun;33(6):524-533.
- 19 **Belaunzarán-Zamudio PF**, Azzoni L, Canaday DH, *et al.* Immunologic effects of maraviroc in HIV-infected patients with severe CD4 lymphopenia starting antiretroviral therapy. A sub-study of the CADIRIS trial. *Pathogens and Immunity.* 2017;2(2):151-77.
- 18 Gutiérrez-Robledo LM, Caro-López E, Guerrero-Almeida ML, Dehesa-Violante M, Rodríguez-Noriega E, García-Lara JM, *et al.* [Results of the First Mexican Consensus of Vaccination in the Adult]. *Gac Med Mex.* 2017 Mar;153(2):190-204.
- 17 Manion M, Andrade BB, DerSimonian R, Gu W, Rupert A, Musselwhite LW, Sierra-Madero JG, **Belaunzarán-Zamudio PF**, *et al.* Country of residence is associated with distinct inflammatory biomarker signatures in HIV-infected patients. *J Virus Erad.* 2017 Jan 1;3(1):24-33.
- 16 De Boni RB, Shepherd BE, Grinsztejn B, Cesar C, Cortés C, Padgett D, Gotuzzo E, **Belaunzarán-Zamudio PF**, *et al.* Substance Use and Adherence Among People Living with HIV/AIDS Receiving cART in Latin America. *AIDS Behav.* 2016 Nov;20(11):2692-2699
- 15 Zitko P, Beltrán C, Mejía F, Celi AP, Greco MM, Afani A, Martínez-Buitrago E, Cassetti I, Lasso M, **Belaunzarán-Zamudio F**, *et al.* Descripción de las características de 44 centros de atención VIH en 11 países de América Latina; Resultados del Taller Latinoamericano de VIH. *Rev Panam Infectol.* 2016;18(1):16-28
- 14 Jacobson JM, Bosinger SE, Kang M, **Belaunzarán-Zamudio P**, *et al.* The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1. *AIDS Res Hum Retroviruses.* 2016 Jul;32(7):636-47.
- 13 Rebeiro PF, Cesar C, Shepherd BE, De Boni RB, Cortés CP, Rodriguez F, **Belaunzarán-Zamudio P**, *et al.* Assessing the HIV Care Continuum in Latin America: progress in clinical retention, cART use and viral suppression. *J Int AIDS Soc.* 2016 Apr 8;19(1):20636.
- 12 Musselwhite LW, Andrade BB, Ellenberg SS, Tierney A, **Belaunzarán-Zamudio PF**, *et al.* Vitamin D, D-dimer, Interferon  $\gamma$ , and sCD14 Levels are Independently Associated with Immune Reconstitution Inflammatory Syndrome: A Prospective, International Study. *EBioMedicine.* 2016 Jan 14;4: 115-23.
- 11 Avila-Funes JA, **Belaunzarán-Zamudio PF**, Tamez-Rivera O, *et al.* Correlates of Prevalent Disability among HIV-Infected Elderly Patients. *AIDS Res Hum Retroviruses.* 2016 Feb; 32(2):155-162.

- 10 Mosqueda-Gómez JL, **Belaunzarán-Zamudio PF**, Barba A, *et al.* Surveillance of Oseltamivir-Resistant Influenza A(H1N1)pdm09 in Guanajuato State, Mexico from 2009 to 2012. *Rev Invest Clin.* 2015 Jul-Aug;67(4):235-9
- 9 **Belaunzarán-Zamudio PF**, Caro-Vega YN, Shepherd BE, *et al.* Monitoring of HIV treatment in seven countries in WHO Region of the Americas. *Bull WHO*, 2015; 93(8): BLT.14.147447.
- 8 Luz PM, **Belaunzarán-Zamudio PF**, Crabtree-Ramírez B, *et al.* CD4 response up to 5 years following combination antiretroviral therapy in HIV-infected patients in Latin America and The Caribbean. *Open Forum Infect Dis (Spring 2015) ofv079.*
- 7 Sierra-Madero JG, Ellenberg SS, Rassool MS, Tierney A, **Belaunzarán-Zamudio PF**, *et al.* Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial. *Lancet HIV* 2014; 1(2): e60-e67
- 6 Crabtree-Ramírez B, Caro-Vega Y, **Belaunzarán-Zamudio F**, Sierra-Madero J. High prevalence of late diagnosis of HIV in México during the HAART era. *Salud Publica de Mexico*, 2012; 54: 506-514
- 5 Hoyo-Ulloa I, **Belaunzarán-Zamudio PF**, Crabtree-Ramirez B, *et al.* Impact of the Immune Reconstitution Inflammatory Syndrome (IRIS) on Mortality and Morbidity in HIV infected patients in Mexico. *Int J Infect Dis* 2011;15(6): e408-14
- 4 Sierra-Madero J, Villasis-Keever A, Méndez P, Mosqueda-Gómez JL, Torres-Escobar I, Gutiérrez-Escolan F, Juárez-Kasusky, I, Magana-Aquino M, Ramos-Santos C, Pérez-Saleme L, Rangel-Frausto S, Antuna-Puente B, Soto-Ramírez LE, Lima V, **Belaunzarán-Zamudio F**, *et al.* Prospective, randomized, open label trial of efavirenz vs lopinavir/ritonavir in HIV+ treatment-naive subjects with CD4+ <200 cell/mm<sup>3</sup> in México. *JAIDS* 2010; 53: 582-588.
- 3 **Belaunzarán-Zamudio, PF**, García-León ML, Wong-Chew RM, *et al.* Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART. *Vaccine* 2009; 27: 7059-64
- 2 Valdés-Ferrer SI, Crispín JC, **Belaunzarán PF**, *et al.* Acetylcholine-esterase inhibitor pyridostigmine decreases T cell overactivation in patients infected by HIV. *AIDS Research & Human Retroviruses* 2009; 25: 749-755.
- 1 García-León ML, Wong-Chew RM, **Belaunzarán PF**, *et al.* La vacunación contra rubéola produce una Respuesta Inmune en Adultos con VIH seronegativos para rubéola Bajo Terapia Antirretroviral Altamente Efectiva. *Enfermedades Infecciosas y Microbiología* 2008; 28(4).

## SCIENTIFIC MEETINGS

**2019**

**10th IAS Conference on HIV Science (IAS 2019).** July 21-24, Mexico City, Mexico

1. Immune-phenotypic characteristics associated with an effective acute-phase response predict a reduced amount of integrated HIV DNA in naïve CD4+ T-cells in patients treated during acute HIV infection
2. HIV care continuum among recently diagnosed individuals in Mexico City

**HIV & Hepatitis in the Americas.** April 4-6 Bogotá, Colombia.

---

1. Barriers to access HIV-healthcare services for women living with HIV in Mexico (Poster 12)
2. Syphilis prevalence among men who have sex with men attending community-based HIV testing clinic in the city of Guadalajara, Mexico (2016-2018). (Poster 27)
3. Modest progress in early linkage to care in Latin American HIV-care centres from the HIV Latin American Workshop Group (2013-2017). (Poster 44)

**27<sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI).** March 4-7 Seattle, WA.

---

1. Antiretroviral Therapy and Kaposi Sarcoma Trends in Latin America. (Abstract 274).
2. Impact of Dual Therapy on the CD4/CD8 Ratio Is Similar to Triple Therapy at 48 weeks (Abstract 492)

**2018**

**Trends in antiretrovirals use in Latin America.** Dec 13-15. Santiago, Chile.

---

Late presentation and mortality: the forgotten goals (invited speaker)

**I Symposium on Liaison Psychiatry.** Dec 6-8. Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico.

---

Integral Healthcare for People Living with HIV (Invited Professor)

**LVIII International Congress. Mexican Society of Nutrition and Endocrinology.** Nov 27-Dec 1<sup>st</sup>. Mérida, Yucatan, Mexico

---

Evaluation of Glycemic Targets in People with HIV and Diabetes.

**XLI National Congress of Internal Medicine.** Nov 21-24. Mérida, Yucatan, Mexico

---

Evaluation of Standards of Medical Care in Diabetes among People with HIV

**IDWeek 2018<sup>TM</sup>,** October 3-7, San Francisco, CA

---

1. Building a Decision Tree with Serial Serology Measurements Improves Classification in a Flavivirus Co-circulation Region (Poster 2081)
2. Frequency of Syphilis Annual Screening Testing, Prevalence of Infection and Re-infection and Associated Characteristics among People Receiving Care for HIV in an HIV/AIDS Care Clinic in Mexico City (2001-2017) (Poster 2270)

**A multidisciplinary approach to meeting the challenge of arboviral diseases in America.** Sep 17-22. Cuernavaca, Morelos. Mexico

---

Clinical aspects of Zika in Mexico. (Invited speaker)

**22<sup>nd</sup> International AIDS Conference.** July 23-27. Amsterdam, Netherlands.

---

Changes in time to ART initiation in adults with high CD4 count in Latin America, 2003-2016 (Abstract THPEC 229)

**IX International Forum on Palliative Care and Pain Management.**

---

Can we still consider AIDS a terminal condition? (Invited Professor)

**HIV & Hepatitis in the Americas 2018.** April 6-8, Rio de Janeiro, Brazil

---

1. Retention in care trends and viral suppression in newly admitted HIV patients in a tertiary centre in Mexico City (Poster 025)
2. Prolonged hospital stays and associated factors in patients receiving care in a HIV/AIDS clinic in Mexico City (Poster 36)

3. Vaccine coverage in adults living with HIV and receiving care in a tertiary care centre in Mexico City, 2005–2016 (Poster 37)
4. Low frequency of screening for anal carcinoma in a cohort of adult men receiving care for HIV in a third-care, referral centre in Mexico City (P044)

### **22nd International Workshop on HIV and Hepatitis Observational Databases.**

March 22-28, 2018. Fuengirola, Spain

---

High Mortality Attributable to Late Presentation and Delayed ART Initiation among Adults Living with HIV Receiving Care in Latin America (oral abstract 86).

### **26<sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI).** March 4-7 Boston, MA.

---

1. Causes of Death and Early Mortality in People with HIV in Mexico (2004-2015) (Abstract 895)
2. Clearance, Persistence, and New HPV Infections in a Mexican MSM – HIV Cohort (Abstract 662)

## **2017**

### **XIX International Symposium on HIV/AIDS.** Aug 24-26. Mexico City, Mexico

---

Mortalidad por VIH en México (HIV-associated mortality in Mexico) (Invited speaker)

### **9th IAS Conference on HIV Science,** Jul 23-26. Paris, France

---

1. Very-Early Treated Acute HIV patients have high naïve-CD4+Tregs recovery with a decreased immune activation (Abstract MOPEA0080).
2. Long-Term Outcomes in Antiretroviral Naïve Patients starting Efavirenz- vs. Boosted Protease Inhibitor-based ART in the Caribbean, Central, and South America network for HIV epidemiology (CCASAnet) (Abstract MOPEB0303).

### **I Congreso Taller Latinoamericano de VIH,** Jun 28. Santiago, Chile

---

Late Presentation and Mortality (invited speaker)

### **CPDD 79th Annual Scientific Meeting.** June 17-22. Montréal, Canada

---

Is substance use associated with HIV cascade in Latin America? (poster 105)

### **XLII Annual Congress of Infectious Diseases and Clinical Microbiology.** May 24-27. Puebla, Mexico

---

Frecuencia de Histoplasmosis Diseminada Progresiva en personas con VIH en la era de la Terapia Antirretroviral Combinada. Revisión Sistemática de la Literatura.

### **HIV & Hepatitis in the Americas 2017.** April 6-8, Rio de Janeiro, Brazil

---

1. Increased age-adjusted mortality and incidence of non-AIDS defining events among people living with HIV enrolled after 50 yo and aging in care in Latin America. A CCASAnet cohort study (oral presentation 0133)
2. Coverage of influenza vaccine (2005–2016) in people living with HIV and receiving care in a tertiary care centre in Mexico City (Poster 038)
3. An interdisciplinary approach based on instant communications to diagnose and immediately treat acute HIV infection in a tertiary care hospital in Mexico City (Poster 039)
4. HIV and aging in Latin America: trends over time and clinical characteristics in the CCASAnet Cohort (Poster 041)
5. Trends in late presentation to care and presentation with advanced HIV disease in Latin America (Poster 042)

**25<sup>th</sup> Conference on Retroviruses and Opportunistic Infections 2017 (CROI).**  
February 23-26 Seattle, USA.

---

Predictors of Immune Recovery after ART in very Advanced Disease. (Abstract 225)

## **2016**

**HIV Drug Therapy Glasgow 2016.** October, 23-26 Glasgow, UK

---

1. Myocardial Inflammatory Changes Before and After Antiretroviral Therapy in HIV infected patients with advanced disease. (Poster 185)
2. High Mortality Attributable to Late Presentation and Delayed ART Initiation in HIV-infected Adults Receiving Care in Latin America. (Poster 340)

**XLIV Congress of the National Medicine Academy of Mexico.** Oct 5-7 León, Mexico.

---

Asociación entre Fragilidad y los Trastornos Neurocognitivos Asociados al VIH en Adultos Mayores de 50 años con VIH/SIDA.

**XLI International Course of Internal Medicine.** June 15-18. Puebla, Mexico

---

Emerging diseases and unexpected complications: Zika virus infection (Invited Professor)

**The 2016 International Conference on Frailty and Sarcopenia Research.** April 28-29 Philadelphia, USA

---

Association between Frailty and Cognitive Impairment among 50 years old and over adults with Human Immunodeficiency Syndrome (HIV/AIDS). (Poster 089)

**HIV & Hepatitis in the Americas 2016.** April 28-30, Mexico City, Mexico

---

What are HIV-infected patients dying from? Data from across the region. (Invited speaker 022)

1. Causes of mortality and time to death in people living with HIV in Mexico City (Poster 005)
2. Dyslipidaemia in transgender women before and after cross-sex hormone treatment and ART (Poster 025)
3. ART initiation rates and first-line regimens in Latin America remain a challenge for WHO Recommendations. (Oral Poster 0224)
4. Significant increase in new HIV infections among young adults in Latin America (Poster 037)
5. Presentation to care with advanced HIV disease is still a problem in Latin America (Poster 038)

**20<sup>th</sup> International Workshop on HIV Observational Databases (IWHOD),** March 30-April 1st, Budapest, Hungary

---

Evaluating the care cascade after antiretroviral therapy initiation in Latin America.

**24<sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI),** Feb 22-25, 2016 Boston, Massachusetts. EUA

---

1. Maraviroc and Immune Recovery in Advanced AIDS. (Abstract 296)
2. Distinctive Dynamics of Phenotypic Cellular Restoration in IRIS. (Abstract 299)

## **2015**



**HIV Symposium: The path towards a cure.** Dec 1<sup>st</sup>, National University of Mexico, Mexico City, Mexico

---

Global Perspectives on HIV (Invited Professor)

**8<sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015),** July 19-22 Vancouver, Canada

---

1. Low frequency of consistent condom use during heterosexual intercourse in prison among male inmates in a State Prison System in Mexico. (WEPEC 612)
2. Assessing the HIV Care Continuum in The Caribbean, Central and South America network for HIV epidemiology (CCASAnet): progress in clinical retention, cART use, and viral suppression. (WEAD0104)
3. Ethnicity impacts inflammatory and coagulation profile in HIV patients. (WEPEA 128)

**Update Course on Medicine and Emergency Medicine.** June 26-27. National Institute of Respiratory Diseases (INER). Mexico City, Mexico

---

Pre-Exposure Prophylaxis (PREP). (Invited Professor)

**2015 NIDA International Forum.** June 12-15, Phoenix, AZ

---

Substance Use and Adherence Among HIV-Infected Persons Receiving ART in Latin America.

**HIV in the Americas 2015,** May 16-18, Mexico City

---

1. Health care provision for transgender people in developing countries. The experience of the first transgender health clinic in Mexico. (Oral presentation 0112)
2. Time to HAART initiation after diagnosis and treatment of opportunistic infections in patients with AIDS in the CCASAnet Cohort (Oral presentation 0123)
3. Model of HIV control and prevention strategy through integration of prevention and care at the primary care level: Mexico City HIV/AIDS Program (Oral presentation 0332)
4. CD4 and HIV-VL monitoring practices and costs in patients on ART in Latin America and the Caribbean (Oral presentation 0333)

**XL Annual Congress of Infectious Diseases and Clinical Microbiology.** May 27-30. San Luis Potosí, Mexico

---

Frequency, clinical characteristics and outcomes of Kaposi's Sarcoma in people with HIV starting antiretroviral therapy.

**Infectious Diseases Symposium for General and Family Practitioners.** Apr 10-11. Mexico City, Mexico

---

Sexually Transmitted Diseases (Invited Professor)

**22<sup>nd</sup> Conference on Retroviruses and Opportunistic Infections 2015 (CROI).** Feb 23 -26 Seattle, USA

---

Vitamin D, D-Dimer, IFN $\gamma$  and sCD14 Predict IRIS in a Prospective Multicenter Study. (Abstract 308)

**2014**

**XVI International Symposium on HIV/AIDS.** Aug 28-30. Mexico City, Mexico

---

Eliminating the HIV epidemic in Mexico (Invited professor)

**2013**

**IDWeek 2013™**, October 2-6, San Francisco, USA

---

Risk Behaviors Associated to HCV-infection Among Inmates in a Prison State System in Mexico

---

**20th Conference on Retroviruses and Opportunistic Infections.** March 3-6. Atlanta, GA

---

Maraviroc does not Prevent IRIS in High Risk Subjects Initiating ART: 24 Week Results of a Randomized, Placebo-Controlled Trial (oral late breaker poster as member of the CADIRIS study team)

---

**XXXVIII Annual Congress of Infectious Diseases and Clinical Microbiology.** Guadalajara, Jalisco.

---

Oseltamivir Resistance Influenza A H1N1 2009 in Guanajuato, Mexico

Risk Behaviors Associated to HCV Infection among Prison Inmates in the State of Guanajuato.

---

**2012**

**XXXVII Annual Congress of Infectious Diseases and Clinical Microbiology.** Apr 25-28. León, Gto. Mexico

---

Prevalence of sexually transmitted diseases and associated risk factors among inmates in the State Prison System of Guanajuato, Mexico

---

**2009**

**5th IAS Conference on HIV Pathogenesis, Treatment & Prevention.** Cape Town, South Africa.

---

Impact of the immune reconstitution inflammatory syndrome (IRIS) on mortality and hospitalization in HIV-infected patients who started HAART in Mexico

---

**2008**

**XVII International AIDS Conference.** Aug 3-8, Mexico DF, Mexico

---

A prospective, randomized, open label trial of efavirenz versus lopinavir/ritonavir-based HAART among antiretroviral therapy naïve, HIV infected individuals presenting for care with CD4 cell counts

---

**60th Annual Meeting of the American Academy of Neurology.** Apr 12-19, Chicago, IL

---

Modulation of In Vivo T Cell Activation by an Acetylcholine Esterase Inhibitor in Patients Chronically Infected with HIV.

---

**2007**

**Federation of Clinical Immunology Societies 2007 (FOCIS).** June 7-11, 2007 San Diego, CA

---

Modulation of In Vivo T Cell Activation by an Acetylcholine-Esterase Inhibitor in Patients Chronically Infected with HIV. Awarded: "FOCIS 2007 Poster of Distinction"

---

**2006**

**V Forum on HIV/AIDS.** State of Mexico Institute of Social Security. Nov 24. Toluca, Mexico

---

---

Tuberculosis and HIV (Invited Speaker)

**XXXVII National Surgeon's Meeting.** Nov 21-25. Mexico DF, Mexico

---

Infections in Diabetic Foot (Invited Professor)

**HIV/AIDS for General Practitioners.** National Institute of Public Health. Oct 2006.  
Mexico DF, Mexico

---

Initiation of Antiretroviral Therapy in HIV-infected Adults (Invited Professor)

**XXXI Annual Congress of Infectious Diseases and Clinical Microbiology.** Jul 12-15. Monterrey, NL. Mexico

---

Diagnosis of Hepatitis B virus Infection (Invited professor)

1. High frequency of osteopenia and osteoporosis in antiretroviral naïve patients with AIDS
2. Long-term evaluation of immune response to Measles vaccine in adults with HIV-infection.
3. Molecular epidemiology of a methicillin-resistant *Staphylococcus aureus* outbreak in a third-care level hospital.
4. Molecular epidemiology of *Pseudomonas aeruginosa* infections in a third-care level hospital.
5. Cytomegalovirus infections in patients with Systemic Lupus Erythematosus. Review of clinical cases

## 2005

**43<sup>rd</sup> annual meeting of the IDSA.** San Francisco, CA

---

Measles Seroprevalence and Immune Response to Measles Vaccine in HIV Infected Adults in Mexico

**3<sup>rd</sup> International AIDS Society Conference.** Rio de Janeiro, Brazil.

---

Measles Seroprevalence and Immune Response to Measles Vaccine in HIV Infected Adults in Mexico

**XXX Annual Congress of Infectious Diseases and Clinical Microbiology.** Mérida, Yucatán. Mexico

---

1. Measles Seroprevalence and Immune Response to Measles Vaccine in HIV Infected Adults in Mexico
2. Multiple Cerebral Abscesses due to *Listeria monocytogenes*: Case Report

## 2004

**XXXI Annual Congress of Infectious Diseases and Clinical Microbiology.** Puebla, Mexico

---

Description of clinical characteristics of a case-series of patients with *Strongyloides stercoralis*

## 2002

**National Gastroenterology Congress.** Queretaro, Mexico

---

Immunosuppression in kidney transplant adult receptors does not affect progression of HCV infection

## GRADUATE AND POST-GRADUATE STUDENTS

---

### 2018 Tutor

---

- 1 **Project:** Evaluation of Standards of Care for Diabetes of Patients  
**Program:** Internal Medicine. School of Medicine. National Autonomous University of Mexico (UNAM)  
**Student:** Rigoberto Doroteo Álvarez Morales

### Tutor

- 2 **Project:** Vaccine coverage, attitudes toward vaccines and reasons for rejecting vaccine application in people living with HIV and receiving care in a tertiary care centre in Mexico City (2005–2016).  
**Program:** Medicine. School of Medicine. Autonomous University of Baja California  
**Student:** Jorge Oggun Cano Torres

### 2017 Advisor

---

- 3 **Project:** Cognitive Behavioral Intervention to modify cognitive appreciation in adults with HIV-infection and its impact over affective status and antiretroviral adherence. A Randomized Controlled Clinical Trial.  
**Program:** Ph.D. in Medical and Health Sciences. School of Medicine. UNAM.  
**Student:** Jessica Mejía

### 2016 Tutor

---

- 4 **Project:** Life conditions leading to disengagement of HIV-diagnosis process after a positive rapid test for HIV-infection. The case of “Clínica Especializada Condesa”  
**Program:** Master’s in sciences in Social Medicine, Metropolitan Autonomous University (UAM)  
**Student:** Gerardo Iván Martínez Vizcaíno

### 2015 Tutor

---

- 5 **Project:** HIV-associated Neurocognitive Disorders in Adults Receiving Care for HIV at the National Institute of Medical Sciences. Long-term Clinical Response after Antiretroviral Therapy Initiation  
**Program:** Infectious Diseases Specialty. School of Medicine. UNAM.  
**Student:** Luis Esteban Ramírez González

### Tutor

- 6 **Project:** Frequency, clinical characteristics and outcomes of Kaposi’s Sarcoma in people with HIV starting antiretroviral therapy.  
**Program:** Diploma in HIV Medicine. School of Medicine. UNAM  
**Alumno:** Ofelia María Rosales Del Real

### 2013 Tutor

---

- 
- 6 **Project:** Prognostic Markers of Immune Recovery in a Cohort of Adults Starting Antiretroviral Therapy with Advanced HIV-disease.  
**Program:** Infectious Diseases Specialty. School of Medicine. UNAM.  
**Alumno:** Alondra López Martínez